Pharmaceutical Innovation Comes at a Price
A Virtuous Cycle of Investment and Challenge Is Essential
Drug Pricing Policy Is Key to Shaping the Environment

Noh Yeonhong, President of the Korea Pharmaceutical and Bio-Pharma Manufacturers Association

Noh Yeonhong, President of the Korea Pharmaceutical and Bio-Pharma Manufacturers Association

View original image

Korea's pharmaceutical and bio-pharma industry has entered an unprecedented growth phase. In 2025, pharmaceutical exports exceeded 10 billion dollars for the first time in history, and technology exports of new drugs reached a record high last year with 22 deals totaling 21 trillion won. Domestically developed new drugs are also drawing attention. Since 1999, a total of 41 Korean new drugs have been approved, 12 of which, or about 30%, have been launched over the past five years and are proving their competitiveness in advanced markets such as the United States. The number of new drug pipelines, which serves as an indicator of future competitiveness, stands at 3,386, ranking third in the world after the United States and China. This is the result of industrial innovation combined with a policy environment that has supported it.


Behind the achievements of domestic companies, which are smaller in scale than global big pharma (large multinational pharmaceutical companies), lie Korean prescription drugs (generic medicines). Korean pharmaceutical companies have built up their new drug development capabilities through a virtuous cycle in which profits generated from Korean prescription drugs are reinvested into research and development (R&D). The problem is that the government's ongoing price-cutting policy for Korean prescription drugs could break this virtuous cycle. If the government treats Korean prescription drugs merely as a tool for reducing National Health Insurance expenditures and proceeds with large-scale price cuts, there are serious concerns that the foundation of the entire industry will be severely shaken, including a contraction in R&D investment, a decline in facility investment, workforce reductions, and a weakening of supply chains.

Does the government truly understand the structure of the pharmaceutical industry?

The driving force behind this drug price reduction policy lies in a lack of understanding of the structure of the domestic pharmaceutical industry. In the United States and Europe, global new drug developers and generic-focused companies are structurally separated. In contrast, Korea's pharmaceutical industry has grown in a structure where many companies conduct new drug R&D using profits from Korean prescription drugs. Korean prescription drugs, which offer safety and efficacy equivalent to original drugs but at lower prices, have played an important role not only in ensuring public access to medicines, but also as a financial foundation for new drug development. Moreover, in the case of the domestic pharmaceutical industry, the vast majority of R&D funding (94% as of 2023) is self-financed by companies.


If a unilateral drug price reduction policy is implemented without taking this reality into account, companies, in order to survive, will be forced to choose short-term performance-oriented strategies instead of high-risk, long-term research. This is highly likely to result in a decline in industrial competitiveness. Given that Korea's pharmaceutical industry still lags behind global big pharma, such a shift would be even more detrimental. The only way we can narrow the gap with them is through innovation. Innovation must be backed by technology, and technology development requires massive investment. An industrial structure in which innovation through investment can be continuously cycled — that is, an environment where companies can take risks and pursue challenges — must be in place. Drug pricing policy is the key factor that determines that environment.

Unilateral policy drive could undermine the foundation of health security

Even more worrying is that a rapid deterioration in profitability could push companies into abandoning the production of delisting-prevention medicines or low-priced essential drugs that are absolutely necessary for the public. This would mean the loss of Korea's health security foundation, which protected public health through a stable supply of medicines during the COVID-19 pandemic.


It is now time to change the paradigm of drug pricing policy. While reducing National Health Insurance expenditures is important, the policy must shift toward a balanced approach that can also drive industrial innovation and growth. Companies can take on the highly uncertain challenge of new drug development only when a stable profit base is maintained. The government's role is not to constrain the industry's challenges, but to encourage and accelerate them. Only then can Korea's pharmaceutical and bio-pharma industry move forward as a sector with true global competitiveness.



Noh Yeonhong, President of the Korea Pharmaceutical and Bio-Pharma Manufacturers Association

At the 'On-site Meeting on Government Drug Price Reform Plan' held on the 22nd of last month at the Korea Pharmaceutical Cooperative meeting room in Hwaseong, Gyeonggi Province, participants are speaking. Photo by Jungyeon Park

At the 'On-site Meeting on Government Drug Price Reform Plan' held on the 22nd of last month at the Korea Pharmaceutical Cooperative meeting room in Hwaseong, Gyeonggi Province, participants are speaking. Photo by Jungyeon Park

View original image


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing